From the world’s largest CAR-T trial program to its first approved MSC drug — a factual briefing on where China’s regenerative medicine stands today.
Registered cell therapy clinical studies (NHC, as of Aug 2024)
PMC, 2024
Domestically developed CAR-T products approved by NMPA (2021–2024)
NMPA
Year-over-year increase in new cell & gene therapy trials registered in 2024
CDE, June 2025
Date of China's first approved stem cell drug — amimestrocel (Ruibosheng)
NMPA Official
China entered the cell therapy era later than the US and Europe, but has scaled faster than any other nation. Between 2005 and 2024, 2,794 cell therapy clinical studies were registered under the National Health Commission alone — and 115 new drug-level trials were added in 2024, a 42% single-year increase.
The critical distinction for international patients: China operates a dual-track regulatory system. Track 1 is NMPA drug approval — the same rigorous pathway as the FDA or EMA. Track 2 is NHC-supervised hospital-based research at 141 registered institutions. Both operate under Good Manufacturing Practice (GMP) standards and mandatory safety oversight.
China’s published clinical outcomes — in peer-reviewed journals including Nature, Journal of Clinical Oncology, and Journal of Hematology & Oncology — are now competitive with Western equivalents, while costs remain 50–70% lower.
China published approximately 728,700 SCI papers in 2023 — roughly one-third of global scientific output — and accounts for 48.4% of “hot papers” and 33.8% of “highly cited papers” per 2024 Clarivate data.
China’s First Approved MSC Therapy
Source: NMPA Official Announcement, January 2025; BioInformant, January 2025
The NMPA grants conditional marketing authorization to amimestrocel injection (Ruibosheng) — China's first commercially approved mesenchymal stem cell therapy. Indication: steroid-refractory acute GVHD in patients aged 14+. Developer: Platinum Life Excellence Biotech, leveraging 3D stem cell culture technology from Tsinghua University.
Ruijin Hospital (Shanghai Jiao Tong University) performs China's first surgery in a registration-directed trial for autologous iPSC-derived cell therapy for Parkinson's disease. Product: UX-DA001 (UniXell Biotech / Chinese Academy of Sciences). At one month, the patient reported significantly improved motor function and sleep quality, with neuroimaging showing increased dopamine transporter activity.
The Medical Products Administration of Hainan's Boao Lecheng International Medical Tourism Pilot Zone approves 12 stem cell and gene therapies under its accelerated access model. Three received official pricing at the March 2025 Boao Forum for Asia: knee OA (¥36,000), heart failure MSC (¥60,000), and COPD airway basal stem cell therapy (¥150,000).
China's Center for Drug Evaluation publishes draft guidance classifying cell and gene therapies under the international Advanced Therapy Medicinal Products (ATMP) framework, aligning China's regulatory standards with the EU and ICH guidelines.
China registers 115 new cell and gene therapy trials in 2024 alone under the NMPA/CDE formal system, a 42% increase over 2023. As of August 2024, the National Health Commission's cumulative registry reaches 2,794 total registered cell therapy clinical studies. China also opens stem cell and gene therapy development to foreign-invested companies operating in free trade zones (Beijing, Shanghai, Guangdong, Hainan).
China approves four domestically developed CAR-T cell therapies, including the world's first CAR-T targeting Claudin18.2 for solid tumors (gastric and pancreatic cancer). By 2024, China operates more CAR-T clinical trials than any other nation, with outcomes showing 79–89% overall response rates in B-cell malignancies and 89.6% ORR in multiple myeloma.
The most clinically advanced stem cell category in China. MSCs derived from umbilical cord, bone marrow, and adipose tissue are under investigation for orthopedic, autoimmune, and cardiac conditions. Ruibosheng (amimestrocel) became China's first approved MSC product in January 2025.
China surpassed the US in CAR-T trial volume and now runs the world's most active CAR-T program. Chinese researchers lead in solid tumor targeting — with unique programs for Claudin18.2 (gastric cancer) and GPC3 (liver cancer) not matched anywhere else.
China entered the iPSC clinical era in March 2025 with the first iPSC Parkinson's surgery at Ruijin Hospital. iPSC-derived MSCs are also under investigation as a standardized, off-the-shelf alternative to donor-tissue MSCs — with multiple differentiation strategies published in 2024.
HSC transplantation is an established, approved therapy for blood cancers and bone marrow failure syndromes. China's top tertiary hospitals perform tens of thousands of HSC transplants annually, with outcomes data routinely published in international journals. Used in combination with CAR-T therapy for relapsed/refractory cases.
The NHC has designated 13 national high-quality stem cell research centers, staffed by over 400 PhD-level researchers. 141 hospitals are authorized to run clinical studies. Geographically, the program clusters in Shanghai (31.6%), Beijing (20.4%), and Jiangsu (9.2%).
| Region | MSC therapy (orthopedic) | CAR-T therapy | Notes |
|---|---|---|---|
| China (regulated) | ¥36,000–¥60,000 ~$5,000–$8,400 USD | ~$150,000 USD | Boao Lecheng approved pricing; CAR-T with Shanghai Hu Hui Bao insurance may cover 50% |
| United States | $25,000–$100,000+ | ~$400,000 USD | Largely out-of-pocket for MSC; CAR-T partially covered for approved indications |
| Germany | $12,000–$25,000 | $300,000–$400,000 USD | EU regulatory framework; some MSC trials open to international patients |
| Switzerland | $20,000–$35,000 | $350,000+ USD | High base costs offset by insurance for local residents |
| China (clinical trial) | Free to eligible participants | Free to eligible participants | NHC-registered trials cover therapy cost; international patient logistics are separate |
Cost data sourced from: Boao Lecheng MPA official pricing (March 2025), MASI Longevity Country Comparison (2025), Sylk Health China Cost Analysis. All prices are approximate and subject to individual protocol complexity.
Yes. China operates a dual regulatory system. The NMPA (National Medical Products Administration) oversees commercial drug approvals — including the January 2025 approval of amimestrocel (Ruibosheng) for acute GVHD. The National Health Commission (NHC) governs hospital-based clinical research at 141 registered institutions. A third pathway operates within the Hainan Boao Lecheng pilot zone, allowing accelerated access to specific experimental therapies under strict expert review. Unregulated clinics charging for unapproved treatments are illegal under Chinese law.
Blood cancers (leukemia, lymphoma, multiple myeloma) via HSC transplant and CAR-T are the most established. MSC therapy is actively trialed for GVHD, rheumatoid arthritis, lupus, Crohn's disease, osteoarthritis, heart failure, COPD, and spinal cord injury. iPSC therapy for Parkinson's disease entered its first Chinese Phase I trial in March 2025. All non-hematology indications are conducted within registered clinical trials, not as commercial treatments.
Costs vary significantly by treatment type and setting. MSC therapy for orthopedic conditions at Boao Lecheng approved facilities costs approximately ¥36,000 (~$5,000 USD) per injection for knee osteoarthritis. CAR-T therapy in China averages ~$150,000 USD versus ~$400,000 USD in the US — a savings of approximately 62%. Shanghai's 'Hu Hui Bao' insurance policy covers up to 50% of CAR-T costs for eligible patients. Clinical trial enrollment at NHC-registered hospitals may be free of charge, though international patient logistics are not covered.
Boao Lecheng is a special economic zone in Hainan Province that allows faster clinical access to experimental cell and gene therapies not yet commercially approved nationally. As of February 2025, 12 stem cell and gene therapies have been approved within the zone. Access is restricted to two hospitals: Ruijin Hospital Hainan Hospital and West China Hospital Lecheng Hospital. All therapies undergo multidisciplinary review by seven specialist disciplines before approval.
China has approved four domestically developed CAR-T products and operates more active CAR-T clinical trials than any country in the world, including the United States. Unique Chinese developments include the world's first Claudin18.2-targeting CAR-T for solid tumors (gastric and pancreatic cancer) — an indication with no equivalent approved therapy in the US. Published outcomes for B-cell malignancies show ORRs of 79–89%, comparable to US-approved products, at roughly one-third the cost.
China's top national stem cell research centers include the Chinese Academy of Medical Sciences / Peking Union Medical College (Beijing), the Institute of Zoology at the Chinese Academy of Sciences (led by Prof. Hongkui Deng), the Shanghai Stem Cell Institute, and university centers at Sun Yat-sen University, Tongji Medical College, and Sichuan University. The NHC has designated 13 high-quality national stem cell research centers staffed by over 400 PhD-level researchers. For international patients, Ruijin Hospital (Shanghai) and West China Hospital (Chengdu) are the primary clinical sites accessible through the Boao Lecheng program.
Not yet as a commercial therapy. UX-DA001, developed by UniXell Biotechnology in collaboration with the Chinese Academy of Sciences, is currently in a Phase I registration-directed trial at Ruijin Hospital in Shanghai. It is the world's first autologous iPSC therapy for Parkinson's disease to hold both NMPA (December 2024) and US FDA (February 2025) investigational new drug approvals. Early results from the first patient (March 2025) show significant motor improvement at one month. Commercial availability is anticipated pending Phase I/II completion.
A 30-minute conversation with one of our physicians is free. We’ll review your case honestly and walk you through which China-based programs — approved, trial, or Boao Lecheng — are relevant to your condition.